All News

FDA accepts priority review of gepotidacin for uncomplicated urogenital gonorrhea, with phase 3 data showing non-inferiority to standard injectable therapy.

The oral peptide that selectively targets IL-23 offers a novel approach to quelling the inflammatory process that underlies plaque psoriasis.

Your daily dose of the clinical news you may have missed.

The obesity and lifestyle medicine specialist says while research on the question continues, a focus on optimizing nutritional health during treatment is essential.

Health information permeates social media platforms exposing Americans to advice, even when they don't want it. The good news? Not many trust it!

Board-certified family physician Sarah Sams, MD, urges physicians to actively engage their communities to build vaccine confidence and combat misinformation.

The Advisory Panel laid out 4 priority actions for clinicians, policy makers, and industry.

The 2 new plasma assays to enhance Alzheimer’s disease research will support disease staging, predicting disease progression, and monitoring treatment outcome.

Your daily dose of the clinical news you may have missed.

Jonathan Bonnet, MD, MPH, encourages primary care clinicians to embrace GLP-1 therapy where appropriate to stem multiple risk factors for downstream chronic diseases.

New data shows pediatric pharmacotherapy prescribing rose but remained infrequent, while nutrition counseling rates changed minimally.

The investigational daily oral GLP-1 RA met the primary endpoint for body weight reduction at 72 weeks and also improved a range of cardiovascular risk factors.

Infectious disease physician Amesh Adalja, MD, explains how PCPs can reframe vaccines as health technology to boost confidence and counter hesitancy.

Your daily dose of the clinical news you may have missed.

Fremanezumab is now the only CGRP antagonist indicated for prevention of migraine in adults and preventive treatment of episodic migraine in pediatric patients.

Since his Senate approval as head of HHS in February, RFK Jr has enacted and/or proposed seismic changes to US vaccine policy that will impact your daily care of patients.

The vasopressin V1b antagonist reduced depressive symptoms, with greater effects in genetically-selected patients using a precision psychiatry approach.